IONS•Ionis Pharmaceuticals’ Q3 revenue rose 54.8% year over year, and adjusted operating income was $87 million. The company lowered 2026 TRYNGOLZA sales guidance to about $50 million while reaffirming other 2026 guidance.
Ionis Pharmaceuticals’ Q3 revenue rose 54.8% year over year, driven by growth in commercial and R&D revenue. Adjusted operating income was $87 million, beating analyst expectations; adjusted operating expenses were $330 million.
The company lowered its 2026 TRYNGOLZA product sales guidance to about $50 million, citing a slower-than-expected launch ramp. It reaffirmed DAWNZERA product sales guidance of $110 million to $120 million, as well as its 2026 total revenue, operating loss and cash guidance.
